These include: demographic, such as age, education and gender [15]; clinical, including initial severity of cognitive impairment, stroke severity [16]; neurological, including lesion side and volume [17]; interventions such as tissue-plasminogen activator (i.e. tPA or alteplase), anticoagulant or antiplatelet medications and their association with hemorrhagic transformation [18]; modifiable risk factors such as diet and lifestyle [19]; and blood-based biomarkers (e.g. cholesterol, vitamin B12, vitamin D, and inflammatory biomarkers) [10, 20, 21]. The gene discussed is PLAT; the disease is Stroke.